 |
|||||||||
Still's Disease & Autoinflammatory Digest: November 2023 |
|||||||||
Advertisement |
|||||||||
StillsNow is an educational resource for physicians and patients, dedicated to Still’s Disease, Autoinflammatory and Febrile disorders. Be sure to subscribe to our monthly StillsNow Podcast on Apple or Android podcast platforms. |
|||||||||
|
Here at Last: Treatment Options for VEXASWe have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to ACR Convergence 2023 there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described… |
||||||||
New Biomarkers and Therapeutics Show Potential in Still's DiseaseAdult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis (sJIA) characterized by sustained fever, salmon-colored rash, and arthritis. AOSD and sJIA are considered the same spectrum of disease with similar pathophysiology occurring in different age groups. Both are characterized by the classic triad of fevers, joint… |
|
||||||||
|
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN VariantsA prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions. While new ACR and EULAR/PRINTO treatment guidelines for sJIA (Still’s disease) promote the early, first-line, use of (IL-1 or IL-6) cytokine inhibitors over methotrexate and glucocorticoids, there has been some concer about… |
||||||||
|
|||||||||
|
|||||||||
|
|||||||||
|
|
|||||||||
|
|
|||||||||
|
|||||||||
